Article
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
The Journal of infectious diseases - 17 Jan 2018
Talal Andrew H, Dumas Emily O, Bauer Barbara, Rejman Richard M, Ocque Andrew, Morse Gene D, Lucic Danijela, Cloherty Gavin A, King Jennifer, Zha Jiuhong, Zhang Hongtao, Cohen Daniel E, Shulman Nancy, Pawlotsky Jean-Michel, Hézode Christophe
Abstract excerpt
Background: It is unknown whether ribavirin (RBV) coadministration modifies the early rate of decline of hepatitis C virus (HCV) RNA in the liver versus plasma compartments, specifically. Methods: This partially randomized, open-label, phase 2 study enrolled treatment-naive, noncirrhotic patients with HCV genotype 1a. Patients were randomized 1:1 into Arms A and B, and then enrolled in Arm C. Patients received...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.